Published in Vaccine Weekly, July 30th, 2003
"To enhance mucosal immune responses using simian-human immunodeficiency virus-like particles (SHIV VLPs) as a mucosal HIV vaccine," Qizhi Yao and colleagues at Baylor College of Medicine in Houston "produced phenotypically mixed, chimeric influenza HA/SHIV 89.6 VLPs and used them to immunize C57B/6J mice intranasally."
Humoral and cellular mucosal immune activity induced by chimeric VLPs was significantly more robust than that elicited by unmodified SHIV particles, Yao and coauthors found.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.